Genetic prognostic factors in childhood acute myeloid leukemia;Prognostische Relevanz genetischer Aberrationen der akuten myeloischen Leukämie bei Kindern und Jugendlichen

Klinische Padiatrie

Volumn 224, Issue 6, 2012, Pages 372-376

  Reinhardt, D ^a   Von Neuhoff, C ^a   Sander, A ^a   Creutzig, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

acute myeloid leukemia; childhood; genetics; prognostic factor

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; GENE MUTATION; HEREDITY; HUMAN; KARYOTYPE; MONOSOMY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 7; CYTARABINE; DNA MUTATIONAL ANALYSIS; ETOPOSIDE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, WILMS TUMOR; GENETIC MARKERS; HUMANS; IDARUBICIN; INFANT; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 84869087785     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1312611     Document Type: Article

References (34)

1. Abrahamsson J., Forestier E., Heldrup J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol: 2011; 29 310 315
2. Balgobind B. V., Raimondi S. C., Harbott J. et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood: 2009; 114 2489 2496
3. Balgobind B. V., Van den Heuvel-Eibrink M. M., De Menezes R. X. et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica: 2011; 96 221 230
4. Coenen E. A., Raimondi S. C., Harbott J. et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood: 2011; 117 7102 7111
5. Cooper T. M., Franklin J., Gerbing R. B. et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the childrens oncology group. Cancer: 2011
6. Corbacioglu S., Kilic M., Westhoff M. A. et al. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood: 2006; 108 3504 3513
7. Creutzig U., Berthold F., Boos J. et al. Verbesserung der Prognose bei Kindern mit AML: Ergebnisse der Studie AML-BFM 93. Klin Padiatr: 2001; 213 1 11
8. Creutzig U., Ritter J., Ludwig W. D. et al. Klassifikation der AML nach morphologischen, immunologischen und zytogenetischen Kriterien - Übersicht unter Berücksichtigung der Subtypen in der Studie AML-BFM-87. Klin Padiatr: 1993; 205 272 280 (Pubitemid 23233370)
9. Creutzig U., Ritter J., Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83as compared with study AML-BFM-78. Blood: 1990; 75 1932 1940 (Pubitemid 20180281)
10. Creutzig U., Zimmermann M., Bourquin J. P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia: 2011
11. Creutzig U., Zimmermann M., Bourquin J. P. et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood: 2011; 118 5409 5415
12. Creutzig U., Zimmermann M., Lehrnbecher T. et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol: 2006; 24 4499 4506 (Pubitemid 46646248)
13. Creutzig U., Zimmermann M., Ritter J. et al. Definition of a standard-risk group in children with AML. Br J Haematol: 1999; 104 630 639 (Pubitemid 29119294)
14. Creutzig U., Zimmermann M., Ritter J. et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia: 2005; 19 2030 2042 (Pubitemid 41741595)
15. Damm F., Thol F., Hollink I. et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia: 2011; 25 1704 1710
16. Goemans B. F., Zwaan C. M., Miller M. et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia: 2005; 19 1536 1542 (Pubitemid 43090396)
17. Harrison C. J., Hills R. K., Moorman A. V. et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28 2674 2681
18. Hasle H., Alonzo T. A., Auvrignon A. et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood: 2007; 109 4641 4647 (Pubitemid 46827753)
19. Hollink I. H., Van den Heuvel-Eibrink M. M., Arentsen-Peters S. T. et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood: 2011; 118 3645 3656
20. Hollink I. H., Van den Heuvel-Eibrink M. M., Arentsen-Peters S. T. et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica: 2011; 96 384 392
21. Hollink I. H., Van den Heuvel-Eibrink M. M., Zimmermann M. et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood: 2009; 113 5951 5960
22. Hollink I. H., Zwaan C. M., Zimmermann M. et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia: 2009; 23 262 270
23. Kalbfleisch J., Prentice R. The Statistical Analysis of Failure Time Data. New York, NY Wiley: 2002
24. Krance R. A., Hurwitz C. A., Head D. R. et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol: 2001; 19 2804 2811 (Pubitemid 32538188)
25. Lehrnbecher T., Ethier M. C., Zaoutis T. et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol: 2009; 147 125 128
26. Lehrnbecher T., Kaiser J., Varwig D. et al. Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. Eur J Clin Microbiol Infect Dis: 2007; 26 735 738 (Pubitemid 47373413)
27. Lie S. O., Abrahamsson J., Clausen N. et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Downs syndrome: results of NOPHO-AML trials. Br J Haematol: 2003; 122 217 225 (Pubitemid 36859606)
28. Meshinchi S., Stirewalt D. L., Alonzo T. A. et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood: 2008
29. Rubnitz J. E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol: 2010; 11 543 552
30. Staffas A., Kanduri M., Hovland R. et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood: 2011; 118 5905 5913
31. Steinbach D., Wilhelm B., Kiermaier H. R. et al. Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. Arch Dis Child: 2011; 96 1026 1032
32. Sung L., Aplenc R., Zaoutis T. et al. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer: 2008; 51 458 460
33. von Neuhoff C., Reinhardt D., Sander A. et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol: 2010; 28 2682 2689
34. Zwaan C. M., Meshinchi S., Radich J. P. et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood: 2003; 102 2387 2394 (Pubitemid 37193574)